First-in-human Study With the Antibody-drug Conjugate SYD985 to Evaluate Safety and Efficacy in Cancer Patients

NCT02277717 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

185

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: SYD985 (trastuzumab vc-seco-DUBA)

Sponsor

Byondis B.V.